An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoring

Proteomics - Clinical Applications

Volumn 5, Issue 9-10, 2011, Pages 532-541

  Egler, Rachel A ^a,b,e   Li, Yiting ^a,b   Dang, Tu Anh T ^c   Peters, Tricia L ^a,b   Leung, Eastwood ^a,b,d   Huang, Shixia ^b,d   Russell, Heidi V ^a,b   Liu, Hao ^b,d   Man, Tsz Kwong ^a,b,d  

^a TEXAS CHILDREN S CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ProteinSimple   (United States)

^d Dan L Duncan Cancer Center   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Biomarkers; Cytokines and chemokines; Neuroblastoma; Relapse

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CD40 LIGAND; EPIDERMAL GROWTH FACTOR; FOTAXIN; INTERLEUKIN 6; PROTEIN MDC; SERUM AMYLOID A; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FUNCTIONAL PROTEOMICS; HUMAN; MALE; MOLECULAR PATHOLOGY; NEUROBLASTOMA; NEUROMONITORING; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RELAPSE; RELIABILITY; SENSITIVITY AND SPECIFICITY; TUMOR CLASSIFICATION; VALIDATION PROCESS;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; NEOPLASM STAGING; NEUROBLASTOMA; PROTEOMICS; RECURRENCE; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 80053642050     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000089     Document Type: Article

References (38)

1. Maris, J. M., Hogarty, M. D., Bagatell, R., and Cohn, S. L., Neuroblastoma. Lancet 2007, 369, 2106-2120.
2. Matthay, K. K., Perez, C., Seeger, R. C., Brodeur, G. M. et al., Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J. Clin. Oncol. 1998, 16, 1256-1264.
3. Lau, L., Neuroblastoma: a single institution's experience with 128 children and an evaluation of clinical and biological prognostic factors. Pediatr. Hematol. Oncol. 2002, 19, 79-89.
4. Maris, J. M., The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr. Opin. Pediatr. 2005, 17, 7-13.
5. Lau, L., Tai, D., Weitzman, S., Grant, R. et al., Factors influencing survival in children with recurrent neuroblastoma. J. Pediatr. Hematol. Oncol. 2004, 26, 227-232.
6. Brodeur, G. M., Maris, J. M., in: Pizzo, P., Poplack, D. (Eds), Neuroblastoma in Principles and practice of pediatric oncology, Lippincott Williams and Wilkins, Philadelphia 2006, 993-1070.
7. Simon, R., Radmacher, M. D., Dobbin, K., McShane, L. M., Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl. Cancer Inst. 2003, 95, 14-18.
8. Kuroda, T., Morikawa, N., Matsuoka, K., Fujino, A. et al., Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma. J. Pediatr. Surg. 2008, 43, 2182-2185.
9. Yagyu, S., Gotoh, T., Iehara, T., Miyachi, M. et al., Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin. Cancer Res. 2008, 14, 7011-7019.
10. Misawa, A., Tanaka, S., Yagyu, S., Tsuchiya, K. et al., RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Br. J. Cancer 2009, 100, 399-404.
11. Combaret, V., Audoynaud, C., Iacono, I., Favrot, M. C. et al., Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res. 2002, 62, 3646-3648.
12. Egler, R. A., Burlingame, S. M., Nuchtern, J. G., Russell, H. V., Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin. Cancer Res. 2008, 14, 7028-7034.
13. Ho, R., Minturn, J. E., Hishiki, T., Zhao, H. et al., Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. 2005, 65, 9868-9875.
14. Raffaghello, L., Cocco, C., Corrias, M. V., Airoldi, I., Pistoia, V., Chemokines in neuroectodermal tumour progression and metastasis. Semin. Cancer Biol. 2009, 19, 97-102.
15. Russell, H. V., Hicks, J., Okcu, M. F., Nuchtern, J. G., CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J. Pediatr. Surg. 2004, 39, 1506-1511.
16. Walker, S. R., Redlinger, R. E., Jr., Barksdale, E. M., Jr., Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression. J. Pediatr. Surg. 2005, 40, 244-249.
17. Ara, T., Song, L., Shimada, H., Keshelava, N. et al., Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 2009, 69, 329-337.
18. Combaret, V., Bergeron, C., Brejon, S., Iacono, I. et al., Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett. 2005, 228, 91-96.
19. Liotta, L. A., Ferrari, M., Petricoin, E., Clinical proteomics: written in blood. Nature 2003, 425, 905.
20. Petricoin, E. F., Liotta, L. A., SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr. Opin. Biotechnol. 2004, 15, 24-30.
21. Rellano-Garcia, M. E., Hu, S., Wang, J., Henson, B. et al., Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis. 2008, 14, 705-712.
22. Nolen, B. M., Marks, J. R., Ta'san, S., Rand, A. et al., Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res. 2008, 10, R45.
23. Li, Y., Dang, T. A., Shen, J., Perlaky, L. et al., Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics. 2006, 6, 3426-3435.
24. He, Q. Y., Zhu, R., Ren, Y., Tam, P. K., Chiu, J. F., Serological protein profiling of neuroblastoma by ProteinChip SELDI-TOF technology. J. Cell Biochem. 2005, 95, 165-172.
25. Malle, E., Sodin-Semrl, S., Kovacevic, A., Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol. Life Sci. 2009, 66, 9-26.
26. Findeisen, P., Zapatka, M., Peccerella, T., Matzk, H. et al., Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J. Clin. Oncol. 2009, 27, 2199-2208.
27. Le, L., Chi, K., Tyldesley, S., Flibotte, S. et al., Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin. Chem. 2005, 51, 695-707.
28. Moshkovskii, S. A., Serebryakova, M. V., Kuteykin-Teplyakov, K. B., Tikhonova, O. V. et al., Ovarian cancer marker of 11.7kDa detected by proteomics is a serum amyloid A1. Proteomics. 2005, 5, 3790-3797.
29. Sandoval, J. A., Turner, K. E., Hoelz, D. J., Rescorla, F. J. et al., Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers. J. Surg. Res. 2007, 142, 268-274.
30. Fielding, C. J., Fielding, P. E., Molecular physiology of reverse cholesterol transport. J. Lipid Res. 1995, 36, 211-228.
31. Ehmann, M., Felix, K., Hartmann, D., Schnolzer, M. et al., Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007, 34, 205-214.
32. Goncalves, A., Esterni, B., Bertucci, F., Sauvan, R. et al., Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006, 25, 981-989.
33. Zhang, Z., Bast, R. C., Jr., Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
34. Sohara, Y., Shimada, H., Minkin, C., Erdreich-Epstein, A. et al., Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res. 2005, 65, 1129-1135.
35. Grossmann, M. E., Brown, M. P., Brenner, M. K., Antitumor responses induced by transgenic expression of CD40 ligand. Hum. Gene Ther. 1997, 8, 1935-1943.
36. Ishida, T., Ueda, R., CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 2006, 97, 1139-1146.
37. Simson, L., Ellyard, J. I., Dent, L. A., Matthaei, K. I. et al., Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol. 2007, 178, 4222-4229.
38. Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H. et al., Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J. Clin. Oncol. 2009, 27, 1007-1013.